NCT03568708View on ClinicalTrials.gov

Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions
Primary Ovarian Insufficiency
Interventions
DRUG

Transdermal Estrogen

In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).

Trial Locations (1)

45229

Cincinnati Children's Hospital, Cincinnati

All Listed Sponsors
collaborator

Patty Brisben Foundation For Women's Sexual Health

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03568708 - Primary Ovarian Insufficiency: Phenotype and Optimal Treatment | Biotech Hunter | Biotech Hunter